Fundz

VST BIO Corporation raised an undisclosed amount in Series A funding led by Coefficient Giving to advance stroke therapeutics.

PRIVATEMar 17, 2026

Round Type

Series A

BiotechnologyHealth CareTherapeuticsBiopharma

Investors

Coefficient Giving

Description

VST BIO Corporation, a San Diego-based biotechnology company, closed an undisclosed amount in Series A funding. The round was led by Coefficient Giving. The company plans to use the funds to advance its lead program into first-in-human studies and expand its platform. William Sessa has been appointed to the Board of Directors as part of the financing.

Quick answer

VST BIO Corporation raised an undisclosed amount in a Series A round, dated March 17, 2026. Investors: Coefficient Giving.

How much did VST BIO Corporation raise?
VST BIO Corporation raised an undisclosed amount in a Series A round on March 17, 2026.
Who invested in VST BIO Corporation?
Coefficient Giving is named as investors in this round.
What does VST BIO Corporation do?
VST BIO Corporation is a preclinical-stage biotechnology company focused on developing stroke therapeutics and vascular diseases.

Source: Fundz verified event record.

Who else raised in Therapeutics and Biopharma around the same time

Companies in the same sectors as VST BIO Corporation that raised within 45 days of this round, from Fundz verified event records.

  • Lighthouse Pharmaceuticals raised $15M (Series A) on April 22, 2026.
  • Sparian Biosciences raised $15M (Grant) on April 13, 2026.
  • Sidewinder Therapeutics raised $137M (Series B) on April 8, 2026.
  • Denali Therapeutics raised $200M (Debt Financing) on March 31, 2026.
  • Tempest Therapeutics raised $2M on March 20, 2026.
  • GenSight Biologics raised $2M (Post-IPO Equity) on March 10, 2026.

Who to call at VST BIO Corporation, and when

A new round usually means VST BIO Corporation is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day VST BIO Corporation raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at VST BIO Corporation, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at VST BIO Corporation. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

VST BIO Corporation

About

VST BIO Corporation is a preclinical-stage biotechnology company focused on developing stroke therapeutics and vascular diseases. Led by CEO Krisztina Zsebo, the company aims to develop antibodies targeting edema and inflammation for ischemic stroke patients. Its lead candidate, VB-001, has shown efficacy in various diseases, including stroke and sepsis. VST BIO is advancing its lead program into first-in-human studies in 2026.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment VST BIO Corporation raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Predictive Intelligence
Strategic

ML-powered predictions for VST BIO Corporation's next move

See what Strategic adds

Funding Insights

What this usually means
Typical timeline to Series B
Series A companies typically raise their next round in 10-18 months

VST BIO Corporation raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.